Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Macrophage Colony Stimulating Factor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Macrophage Colony Stimulating Factor. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-004674-27 Sponsor Protocol Number: 14076 Start Date*: 2007-02-14
    Sponsor Name:Dutch Kidney Foundation
    Full Title: Effect of GM-CSF on development of antigen-specific T cell responses following hepatitis B vaccination
    Medical condition: Haemodialysis patients are susceptible for infections due to a continuous mildly activated immune system. About 40% of the haemodialysis patients does not respond to the standard HBV vaccination pr...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018487 GM-CSF prophylaxis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001654-21 Sponsor Protocol Number: KKS-279 Start Date*: 2020-09-16
    Sponsor Name:Justus-Liebig-University Gießen
    Full Title: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia
    Medical condition: COVID-19 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005772-16 Sponsor Protocol Number: HEH-SF-01 Start Date*: 2016-06-22
    Sponsor Name:Department of Surgery, Herlev Hospital
    Full Title: The safety and pharmacokinetics of intraperitoneal administration of granulocyte-macrophage colony-stimulating factor, fosfomycin, and metronidazole in patients undergoing appendectomy for uncompli...
    Medical condition: We intend to investigate the safety of treating secondary infectious peritonitis due to uncomplicated appendicitis with intraperitoneally administered fosfomycin, metronidazole and GM-CSF.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10000677 Acute appendicitis LLT
    19.0 100000004848 10053349 Pharmacokinetic study LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000878-30 Sponsor Protocol Number: 209564 Start Date*: 2020-02-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-centre long-term extension study to assess the safety and efficacy of GSK3196165 in the treatment of rheumatoid arthritis.
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Ongoing) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) HU (Prematurely Ended) EE (Completed) DE (Prematurely Ended) LV (Completed) BG (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001717-20 Sponsor Protocol Number: COVIDIOL Start Date*: 2020-04-20
    Sponsor Name:Fundación para la Investigación Biomédica de Córdoba
    Full Title: Prevention and treatment with Calcifediol of Coronavirus COVID-19-induced acute respiratory syndrome (SARS)
    Medical condition: Severe Acute Respiratory Syndrome in subjects with COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061986 SARS LLT
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000868-18 Sponsor Protocol Number: 202018 Start Date*: 2019-12-02
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) LT (Completed) ES (Completed) BE (Completed) CZ (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004864-69 Sponsor Protocol Number: HSJD-HR-NB-Ch14.18 Start Date*: 2014-05-21
    Sponsor Name:Fundació Sant Joan de Deu de Barcelona
    Full Title: Phase II single arm institutional study to assess Dinutuximab combined with the cytokines granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-2 in patients with high-risk neuroblastoma...
    Medical condition: High-risk neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001829-40 Sponsor Protocol Number: 201 Start Date*: 2019-01-02
    Sponsor Name:Y-mAbs Therapeutics A/S
    Full Title: A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete...
    Medical condition: Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000867-26 Sponsor Protocol Number: 201791 Start Date*: 2019-12-10
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) PL (Prematurely Ended) BG (Prematurely Ended) EE (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020435-40 Sponsor Protocol Number: LUC 10-002 Start Date*: 2010-06-23
    Sponsor Name:Centre du Cancer
    Full Title: Phase I/II study of peptide vaccination associated with tumoral immunomodulation with proinflammatory cytokines and imiquimod in patients with advanced metastatic melanoma
    Medical condition: metastatic melanoma patients with regional disease (any T; N2c or N3; M0) or with distant metastatic disease ( any T; any N; M1a, M1b or M1c), except uncontrolled brain or CNS metastases, and eleva...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000797-39 Sponsor Protocol Number: 201790 Start Date*: 2019-11-22
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with methotrexate in participants with mo...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LV (Completed) ES (Completed) PL (Completed) LT (Completed) CZ (Completed) HU (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-003957-14 Sponsor Protocol Number: KCP-330-023 Start Date*: 2017-03-14
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myelom...
    Medical condition: Relapsed or refractory multiple myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GR (Completed) AT (Completed) CZ (Completed) BE (Completed) ES (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000461-10 Sponsor Protocol Number: ISRCTN43482138 Start Date*: 2006-08-25
    Sponsor Name:The Royal Liverpool University Hospital NHS Trust
    Full Title: A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination gemcitabine and capecitabine therapy with concurrent and sequential chemoimmunotherapy using a tel...
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033633 Pancreatic neoplasms malignant (excl islet cell and carcinoid) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001894-15 Sponsor Protocol Number: 2014-856 Start Date*: 2015-01-19
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Administration de GRanulocyte–Macrophage Colony-stimulating Factor (GM-CSF) pour diminuer les Infections acquises en réanimation au cours de l’immunoDépression induite par le sepsis.Etude multicen...
    Medical condition: sepsis sévère ou choc septique dans les 24 premières heures de présence en réanimation
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005036-26 Sponsor Protocol Number: FXT-05 Start Date*: 2011-11-29
    Sponsor Name:Funxional Therapeutics Ltd
    Full Title: An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease
    Medical condition: Asthma Chronic obstructive pulmonary disease Rheumatoid arthritis Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001724-35 Sponsor Protocol Number: AMASCIS-02 Start Date*: 2020-06-16
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario de La Paz (FIBHULP)
    Full Title: AMASCIS-02. ALOGENIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN ISCHEMIC STROKE. A PHASE IIB MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL.
    Medical condition: Moderate-severe ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002532-28 Sponsor Protocol Number: ThymoHEMO1206 Start Date*: 2007-11-28
    Sponsor Name:Genzyme Europe BV
    Full Title: A Phase II Study of Efficacy of Rabbit Antithymocyte Globulin (rATG) in patients with Low and Itermediate-1 Risk Mylodysplastic Syndrome
    Medical condition: Low And Intermediate-1 Risk Myelodysplastic Syndrome in adult patients 70 years or younger
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) FR (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005787-22 Sponsor Protocol Number: EP395-003 Start Date*: 2022-07-21
    Sponsor Name:EpiEndo Pharmaceuticals
    Full Title: A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of EP395 in patients with chronic obstructive pulmonary disease (COPD)
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001759-42 Sponsor Protocol Number: 214094 Start Date*: 2020-05-20
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.
    Medical condition: Severe pulmonary COVID-19 related disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002211-26 Sponsor Protocol Number: PX115.1.1-201 Start Date*: 2006-09-10
    Sponsor Name:Pharmexa A/S
    Full Title: “Heptovax” - Ensayo de fase II, abierto, para evaluar la seguridad y la eficacia de GV1001 para el carcinoma hepatocelular avanzado. (CHC).
    Medical condition: Carcinoma hepatocelular avanzado
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019828 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:24:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA